CERo Therapeutics Holdings, Inc. Secures Two Patents, Strengthening IP Portfolio for Cancer Therapeutics

Strategic Insights -

CERo Therapeutics Holdings, Inc. has announced the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111, in addition to a patent granted in Japan, further solidifying its intellectual property portfolio. These developments bring the total number of granted patents and allowed applications covering CER-1236 and its platform technology to 20, setting the company up for success in the competitive field of cellular immunotherapy.

Key Takeaways:

  • The company has received a Notice of Allowance from the U.S. Patent and Trademark Office for its Application 19/019,111, which provides comprehensive protection for CER-1236 and its use in treating cancer through 2041.
  • The Japanese patent granted to CERo Therapeutics Holdings, Inc. protects the CER platform, further expanding the company's intellectual property portfolio.
  • CERo's total number of granted patents and allowed applications now stands at 20, covering both domestic and international markets.
  • The intellectual property portfolio is expected to support the company's next-generation engineered T cell therapeutics for the treatment of cancer, particularly in the development of CER-1236 for hematologic malignancies.
  • CEO Chris Ehrlich emphasizes the significance of this development, stating that the company is in a "strong regulatory position with regard to exclusivity" and continuing to make progress in its ongoing Phase 1 clinical trial.

Statistics:

  • The company's intellectual property portfolio now comprises 20 granted patents and allowed applications covering CER-1236 and its platform technology internationally.
  • The U.S. patent that will issue will provide protection for CER-1236 through 2041.
  • The Japanese patent protects the CER platform, expanding the company's local intellectual property portfolio.
  • CERo has announced Fast Track and Orphan Drug Designations from the FDA, solidifying its regulatory position.

Sources:

  • Globe Newswire, "CERo Therapeutics Holdings, Inc. Receives Notice of Allowance for Patent Application and Issues New Patent in Japan" on September 09, 2025.